Toyota Recalls 42,000 Corolla Cross Hybrids Over Power-Brake Issue
By Dean Seal
Toyota Motor recalled more than 42,000 Corolla Cross Hybrids over a software error that may result in a loss of power-brake assist when turning corners.
The National Highway Traffic Safety Administration said in a report that the error in the skid-control electronic-control unit can be fixed by dealers with a software update at no cost.
The regulator's report, dated Sept. 20, said not all of the affected vehicles were sold in the U.S.
The recall applies to 2023 and 2024 model Corolla Cross Hybrids with a specific brake-actuator assembly supplied by Robert Bosch GmbH's BhP Plant in Germany that contained specific skid-control electronic-unit software.
Other Toyota vehicles are equipped with Bosch-supplied brake actuators with similar software, the report said. The automaker is looking into whether the software issue is affecting those vehicles.
NHTSA said a loss of power-brake assist can extend the distance required to stop, increasing the risk of a crash.
The report didn't indicate whether any crashes have been reported in connection with the software error.
Owners of the affected vehicles will be notified by mail on Nov. 5.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 27, 2024 08:01 ET (12:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks